While Korean biopharma companies’ out-licensing deals have remained lackluster in the past couple of years, activity around emerging modalities, led by ADCs, have been increasing in line with global trends.
As South Korea aims to foster the development of global blockbuster drugs and top-tier internationalized biopharma firms in the coming years, amid limited financial and labor resources as well as other road blocks, it is crucial for companies to adopt more efficient and effective strategies along with the government’s strong support.
A new policy report from the Korea Pharmaceutical and Bio-Pharma Manufacturers’ Association (KPBMA) notes that licensing activities and mergers and...
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.
South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.
AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get those submissions in by this date. Sponsorship opportunities and tables for the event are also available.
